This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Activation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Factor XIIa, activated Hageman factor, triggers the plasmin fibrinolytic system. As XIIa also triggers the intrinsic pathway of coagulation, this is one means of negative feedback to prevent coagulation progressing indefinitely.

XIIa catalyses the conversion of precursor proteins, circulating in the plasma, into plasminogen activators. Some plasminogen activator is derived directly from local tissue e.g. endothelial cells.

Plasminogen activators are serine enzymes which cleave plasminogen. Plasminogen is a high molecular weight serum beta-globulin which localises to fibrin within a thrombus. Plasminogen is broken down into plasmin and other peptides.

Certain bacteria may produce plasmin directly by secretion of natural streptokinase.

Plasmin is a trypsin-like enzyme which breaks down:

  • polymerized fibrin into fibrin degradation products - FDP's - which include D-dimers
  • fibrinogen
  • factor II
  • factor V
  • factor VIII
  • complement into active components

Many feedback mechanisms exist e.g.:

  • local plasmin inhibitors, antiplasmins, which prevent unlimited fibrin degradation
  • fibrin fragments, which inhibit the local formation of fibrin by providing binding sites for the plasminogen activator, tPA

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.